Prophecy DeFis Wholly Owned Subsidiary Generates Over $2.0M in Returns in First 90 Days of Operations from $3.65M in Deployed Capital

Prophecy DeFi Inc. ("Prophecy DeFi", "PDFI" or the "Company") (CSE: PDFI) is pleased to provide an operational update on its wholly owned subsidiary, Layer2 Blockchain Inc. ("Layer2" or the "Subsidiar ...

Plus Therapeutics Announces FDA Clearance of Investigational New Drug Application for 186RNL for the Treatment of Leptomeningeal Metastases

Patient accrual for the Phase 1 dose escalation clinical trial of 186RNL (ReSPECT-LM) is expected in the fourth quarter of 2021 AUSTIN, Texas, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc.